Dramatic OS Boost with Kisqali in Young Breast Ca Patients

June 03, 2019 8:50 AM | Grant Dvorak (Administrator)

June 3, 2019, MedPage Today 

CHICAGO -- Adding ribociclib (Kisqali) to endocrine therapy significantly prolonged survival in women with advanced HR-positive/HER-negative breast cancer, with a 29% lower risk of death, a researcher reported here. 

Read more.

Powered by Wild Apricot Membership Software